IN BRIEF: Apollon eyes US investors and "up-listing options"

Apollon Formularies PLC - London-based medical cannabis pharmaceutical firm - Advancing ...

Alliance News 9 February, 2022 | 8:26PM
Email Form Facebook Twitter LinkedIn RSS

Apollon Formularies PLC - London-based medical cannabis pharmaceutical firm - Advancing application to join OTCQB Market in US. Says shares will continue to trade on Aquis Stock Exchange. "The company decided to undertake this application for a second trading platform for its shares at the request of several US based investors and believes that cross trading on the OTCQB will provide enhanced investor benefits, including easier access for potential investors in North America, increased trading hours and improved trading liquidity,"

Apollon says. Company adds it is also exploring "other possible up-listing options", including local and international exchanges. "The company will maintain its existing AQSE listing, in addition to any additional up-listing it may undertake," Apollon adds.

Current stock price: 2.5 pence

12-month change: down 64%

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Apollon Formularies PLC

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures